US Market Entry Flow Neuroscience plans a U.S. launch of its Flow device as a prescription-only treatment in Q2 2026, presenting a timely entry point for medical distributors, clinics, and payer discussions in a growing at-home neuromodulation market.

Clinical Proof & Scale backed by a pivotal Nature Medicine RCT and extensive RWE from over 60,000 patients, Flow can be positioned to consort with healthcare providers and payers seeking evidence-based at-home depression therapies with strong efficacy and tolerability.

Strategic Partnerships Historic collaborations with Pharma Vends and Curebase for at-home headset trials indicate openness to co-development and trial-based adoption, suggesting opportunities with pharma, CROs, and clinical research networks.

Global Accessibility Mission to provide evidence-based brain stimulation worldwide as standalone or adjunct care creates multi-market sales angles, including clinics, telemedicine platforms, and durable medical equipment channels in regions with rising mental health demand.

Funding & Growth With $13M in funding and early-stage investor interest from groups like naturalX and Kirin, there is momentum for channel investments, regional distribution deals, and reseller partnerships to accelerate market penetration.